Inside the research
HCA Healthcare, Inc.
HCA Research profile · latest available data
Price overview
$435.61
▲ +12.13 (+2.9%)
| 52w hi | $542.23 |
|---|---|
| 52w lo | $359.93 |
| Vol | 1.02M |
| As of | 25 Sep 2026 |
The Verdict
Our score -0.05
| Short | -0.34 |
|---|---|
| Medium | +0.05 |
| Long | +0.35 |
computed 2026-09-27
Key fundamentals
HCA Healthcare, Inc.
Healthcare · Medical Care Facilities
| Market cap | $94.31B |
|---|---|
| Enterprise value | $148.17B |
| Trailing P/E | 14.60x |
| Forward P/E | 13.61x |
| EV / EBITDA | 9.41x |
| P / S (ttm) | 1.24x |
| Profit margin | 8.8% |
| Revenue growth | +8.7% |
| Earnings growth | +11.6% |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.31 | |
| Sector | +0.08 | |
| Technical | -0.21 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
HCA Healthcare, Inc., through its subsidiaries, provides health care services in the United States. The company owns, manages, and operates hospitals, ASCs, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, radiation and oncology therapy centers, as well as rehabilitation and physical therapy centers, physician practices, home health agencies, hospices, outpatient physical therapy providers, home and community-based services providers, and various other facilities. Its general and acute care hospitals offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic services, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. The company was formerly known as HCA Holdings, Inc. HCA Healthcare, Inc. was founded in 1968 and is headquartered in Nashville, Tennessee.
Risk Metrics
| Beta vs SPX | 0.25 |
|---|---|
| Corr SPX | 0.14 |
| Annual vol | 29.7% |
| Annual ret | +8.1% |
| Sharpe | 0.27 |
| Max DD | -33.7% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $513.10 |
|---|---|
| High / Low | $635.00 / $396.00 |
| Median | $520.00 |
| Analysts | 21 |
| Strong Buy | 2 | |
|---|---|---|
| Buy | 13 | |
| Hold | 9 | |
| Sell | 1 | |
| Strong Sell | 0 |
Recent rating actions
| 2026-04-27 | Wells Fargo | → Equal-Weight |
| 2026-04-27 | Truist Securities | → Buy |
| 2026-04-27 | TD Cowen | → Buy |
| 2026-04-27 | Stephens & Co. | → Overweight |
| 2026-04-27 | RBC Capital | → Outperform |
| 2026-04-27 | Oppenheimer | → Outperform |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-07-29 | Material Obligation, Other Material Event | read |
| 2026-07-24 | Earnings Release, Reg FD Disclosure… | read |
| 2026-07-14 | Earnings Release, Reg FD Disclosure… | read |
| 2026-06-18 | Officer / Director Change | read |
| 2026-04-30 | Material Agreement, Material Obligation… | read |
| 2026-04-28 | Shareholder Vote | read |
| 2026-04-27 | Other Material Event, Exhibits | read |
| 2026-04-24 | Earnings Release, Reg FD Disclosure… | read |
| 2026-02-25 | Officer / Director Change, Exhibits | read |
| 2026-01-27 | Earnings Release, Reg FD Disclosure… | read |
| 2025-10-31 | Material Agreement, Material Obligation… | read |
| 2025-10-27 | Other Material Event, Exhibits | read |
Flow & Concentration
| Insider 180d net | $0 |
|---|---|
| Insider buys / sells | 0 / 0 |
| Insider bias | Neutral |
| 13F holders | 10 |
| Top-5 share | 95.7% |
| HHI | 3,448 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| State Street Corp | $2.91B | 7.47M |
| Norges Bank (Norway sovereign) | $1.28B | 3.30M |
| Fidelity / FMR LLC | $636.50M | 1.63M |
| Capital Research / Capital World | $257.35M | 660.05K |
| Citadel Advisors | $234.82M | 602.26K |
| AQR Capital Management | $87.62M | 225.25K |
| Bridgewater Associates | $79.23M | 203.20K |
| Millennium Management | $64.19M | 164.63K |
| Renaissance Technologies | $7.25M | 18.60K |
| T. Rowe Price Group | $99.74K | 255.81K |
As of 2026-06-30
Connections
Parents: Capital Division
Dividends
| Yield (TTM) | 0.34% |
|---|---|
| $ / share (TTM) | $1.50 |
| 5y CAGR | +30.2% |
Annual dividend per share
| 2021 | $1.92 |
|---|---|
| 2022 | $2.24 |
| 2023 | $2.40 |
| 2024 | $2.64 |
| 2025 | $2.88 |
| 2026 | $0.78 |
SEC Filings
The Long Run
FY 2011–2025 · 15 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $70.60B | +8.3% | |
| Net income | $5.76B | +6.3% | |
| Cash from ops | $9.43B | +10.7% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $421.59 | $435.78 | $420.00 | $435.61 | 1.02M |
| Sep 24 | $437.36 | $442.21 | $423.39 | $423.48 | 1.05M |
| Sep 23 | $441.42 | $446.36 | $433.83 | $436.48 | 1.31M |
| Sep 22 | $426.37 | $442.52 | $426.37 | $438.12 | 1.50M |
| Sep 21 | $427.75 | $434.07 | $423.43 | $425.97 | 1.42M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →